Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Colorcon
Baxter
Boehringer Ingelheim
Moodys

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Penclomedine

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Penclomedine: Sponsors, patents, clinical trial progress

Penclomedine is an investigational drug.

There have been 6 clinical trials for Penclomedine. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.

The most common disease conditions in clinical trials are Neoplasms, Neoplasms, Second Primary, and Brain Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), DEKK-TEC, Inc., and Icahn School of Medicine at Mount Sinai.

There are fifty-nine US patents protecting this investigational drug and five hundred and twelve international patents.

Recent Clinical Trials for Penclomedine
TitleSponsorPhase
A Phase I Study of DM-CHOC-PEN in Pediatric and Adolescent Subjects With Advanced CancersDEKK-TEC, Inc.Phase 1
Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome in Patients With Brain TumorsDetroit Clinical Research Center, Farmington Hills, Lansing and Owasso, MIPhase 2
Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome in Patients With Brain TumorsIcahn School of Medicine at Mount SinaiPhase 2

See all Penclomedine clinical trials

Clinical Trial Summary for Penclomedine

Top disease conditions for Penclomedine
Top clinical trial sponsors for Penclomedine

See all Penclomedine clinical trials

US Patents for Penclomedine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Penclomedine   Start Trial Methods and systems for predicting cancer outcome H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL) University of South Florida (Tampa, FL)   Start Trial
Penclomedine   Start Trial Methods and compositions for the treatment of a host with a cellular proliferative disease Matrix Pharmaceutical, Inc. (Menlo Park, CA)   Start Trial
Penclomedine   Start Trial Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof Pharmacia & UpJohn AB (Stockholm, SE)   Start Trial
Penclomedine   Start Trial Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof Pharmaciaand Upjohn AB (Stockholm, SE)   Start Trial
Penclomedine   Start Trial Self-emulsifiable formulation producing an oil-in-water emulsion Yissum Research Development Company of the Hebrew University of Jerusalem (Jerusalem, IL)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Penclomedine

Drugname Country Document Number Estimated Expiration Related US Patent
Penclomedine European Patent Office 1894131 2025-02-25   Start Trial
Penclomedine World Intellectual Property Organization (WIPO) 2005083128 2024-02-25   Start Trial
Penclomedine World Intellectual Property Organization (WIPO) 2006093507 2024-02-25   Start Trial
Penclomedine Austria 220894 2013-12-29   Start Trial
Penclomedine Australia 1438695 2013-12-29   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Moodys
Mallinckrodt
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.